Literature DB >> 16644118

Fluoxetine increases cerebral white matter NAA/Cr ratio in patients with multiple sclerosis.

Jop P Mostert1, Paul E Sijens, Matthijs Oudkerk, Jacques De Keyser.   

Abstract

Axonal degeneration in multiple sclerosis (MS) may be caused by mitochondrial dysfunction and is associated with decreased levels of N-acetylaspartate (NAA) as measured with 1H-magnetic resonance spectroscopy (MRS). Fluoxetine stimulates astrocytic glycogenolysis, which serves as an energy source for axons. Eleven patients with MS received fluoxetine orally 20 mg a day during the first week, and 40 mg a day during the second week. The mean NAA/Creatine ratio in cerebral white matter of the MS patients increased from 1.77 at baseline to 1.84 at the end of the second week (p=0.007). These findings show evidence for a reversible axonal dysfunction in patients with MS and provide a rationale for investigating whether fluoxetine has neuroprotective effects in MS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16644118     DOI: 10.1016/j.neulet.2006.03.042

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  14 in total

Review 1.  N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology.

Authors:  John R Moffett; Brian Ross; Peethambaran Arun; Chikkathur N Madhavarao; Aryan M A Namboodiri
Journal:  Prog Neurobiol       Date:  2007-01-05       Impact factor: 11.685

Review 2.  White-matter astrocytes, axonal energy metabolism, and axonal degeneration in multiple sclerosis.

Authors:  Melissa Cambron; Miguel D'Haeseleer; Guy Laureys; Ralph Clinckers; Jan Debruyne; Jacques De Keyser
Journal:  J Cereb Blood Flow Metab       Date:  2012-01-04       Impact factor: 6.200

3.  Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia.

Authors:  Meredith A Reid; Luke E Stoeckel; David M White; Kathy B Avsar; Mark S Bolding; N Shastry Akella; Robert C Knowlton; Jan A den Hollander; Adrienne C Lahti
Journal:  Biol Psychiatry       Date:  2010-06-08       Impact factor: 13.382

4.  Reproducibility over a 1-month period of 1H-MR spectroscopic imaging NAA/Cr ratios in clinically stable multiple sclerosis patients.

Authors:  J P Mostert; Y Blaauw; M W Koch; A J Kuiper; J M Hoogduin; J De Keyser
Journal:  Eur Radiol       Date:  2008-04-04       Impact factor: 5.315

Review 5.  Therapeutic potential of fluoxetine in neurological disorders.

Authors:  Jop P Mostert; Marcus W Koch; Marco Heerings; Dorothea J Heersema; Jacques De Keyser
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

6.  Targeting phosphocreatine metabolism in relapsing-remitting multiple sclerosis: evaluation with brain MRI, 1H and 31P MRS, and clinical and cognitive testing.

Authors:  Melissa Cambron; Tatjana Reynders; Jan Debruyne; Harmen Reyngoudt; Annemie Ribbens; Erik Achten; Guy Laureys
Journal:  J Neurol       Date:  2018-09-05       Impact factor: 4.849

Review 7.  Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015-2020.

Authors:  Niklas Huntemann; Leoni Rolfes; Marc Pawlitzki; Tobias Ruck; Steffen Pfeuffer; Heinz Wiendl; Sven G Meuth
Journal:  Drugs       Date:  2021-06-04       Impact factor: 9.546

8.  Drug repurposing: a systematic approach to evaluate candidate oral neuroprotective interventions for secondary progressive multiple sclerosis.

Authors:  Hanna M Vesterinen; Peter Connick; Cadi M J Irvine; Emily S Sena; Kieren J Egan; Gary G Carmichael; Afiyah Tariq; Sue Pavitt; Jeremy Chataway; Malcolm R Macleod; Siddharthan Chandran
Journal:  PLoS One       Date:  2015-04-09       Impact factor: 3.240

9.  The effect of fluoxetine on progression in progressive multiple sclerosis: a double-blind, randomized, placebo-controlled trial.

Authors:  Jop Mostert; Thea Heersema; Manju Mahajan; Jeroen Van Der Grond; Mark A Van Buchem; Jacques De Keyser
Journal:  ISRN Neurol       Date:  2013-07-29

10.  Fluoxetine in progressive multiple sclerosis (FLUOX-PMS): study protocol for a randomized controlled trial.

Authors:  Melissa Cambron; Jop Mostert; Patrick Haentjens; Marie D'Hooghe; Guy Nagels; Barbara Willekens; Dorothea Heersema; Jan Debruyne; Wim Van Hecke; Luc Algoed; Nina De Klippel; Erwin Fosselle; Guy Laureys; Henri Merckx; Bart Van Wijmeersch; Ludo Vanopdenbosch; Wim Verhagen; Raymond Hupperts; Gerald Hengstman; Veronique Michiels; Annick Van Merhaegen-Wieleman; Jacques De Keyser
Journal:  Trials       Date:  2014-01-25       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.